• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    William Blair initiated coverage on Mesoblast with a new price target

    3/9/23 9:06:40 AM ET
    $MESO
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $MESO alert in real time by email
    William Blair initiated coverage of Mesoblast with a rating of Outperform and set a new price target of $8.00
    Get the next $MESO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MESO

    DatePrice TargetRatingAnalyst
    12/23/2024Buy → Hold
    Jefferies
    9/24/2024$12.00Hold → Buy
    Maxim Group
    8/29/2024Hold → Buy
    Jefferies
    7/23/2024$4.00 → $11.00Neutral → Overweight
    Piper Sandler
    8/31/2023Hold → Buy
    Jefferies
    8/7/2023Buy → Hold
    Maxim Group
    8/4/2023$7.00 → $2.00Overweight → Neutral
    Piper Sandler
    8/4/2023Outperform → Mkt Perform
    William Blair
    More analyst ratings

    $MESO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mesoblast downgraded by Jefferies

      Jefferies downgraded Mesoblast from Buy to Hold

      12/23/24 7:24:07 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast upgraded by Maxim Group with a new price target

      Maxim Group upgraded Mesoblast from Hold to Buy and set a new price target of $12.00

      9/24/24 8:11:34 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Mesoblast upgraded by Jefferies

      Jefferies upgraded Mesoblast from Hold to Buy

      8/29/24 7:56:03 AM ET
      $MESO
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care